In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine Safe and sound dosing program. Supplemental individuals might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "insert-on" therapy. In https://jesseg444seo6.blogofchange.com/profile